Document ID: chunk:federal_register_of_legislation:F2025C00211:reg:5:p5
Version: federal_register_of_legislation:F2025C00211
Segment Type: reg
Provision Reference: reg 5 (pt 5/9)
Character Range: 101535–104068

business are situated, the holder of a licence authorising the applicant to sell or supply the drug at or from those premises; or
 (iii) where subparagraphs (i) and (ii) do not apply—the drug is required by the applicant for medical or scientific purposes;
 (c) in the case of a drug, other than methaqualone, that is not included in Schedule 1 or 2 to the Single Convention:
 (i) where the drug is required by the applicant for the manufacture of a drug at certain premises and, under a law of the State or Territory in which those premises are situated, the manufacture of the drug is prohibited unless a licence to manufacture the drug has been granted—the applicant is, for the purposes of that law, the holder of a licence authorising the applicant to manufacture the drug at those premises;
 (ii) where the drug is required by the applicant for the purposes of the applicant's business as a seller or supplier of drugs and, under a law of the State or Territory in which the premises at or from which the applicant conducts that business are situated, the sale or supply of the drug is prohibited unless a licence to sell or supply the drug has been granted—the applicant is, for the purposes of that law, the holder of a licence authorising the applicant to sell or supply the drug at or from those premises; or
 (iii) where subparagraphs (i) and (ii) do not apply and the drug is a drug referred to in paragraph (a) of the definition of drug in subregulation (20)—the drug is required by the applicant for medical or scientific purposes;
 (ca) where the drug is methaqualone—the drug is required for use by the applicant or by another person solely for scientific purposes; and
 (d) proper arrangements have been made by the applicant for the safe transportation and safe custody of the drug after the drug has been delivered for home consumption.
 (11) A permission to import a drug shall be in writing and shall specify:
 (a) the name and address of the holder of the permission;
 (b) the name of the supplier of the drug and the supplier's address in the country from which the drug is exported;
 (c) the name by which the drug is commonly known and the international non‑proprietary name (if any) of the drug;
 (d) the quantity of the drug that the holder of the permission may import;
 (e) where the drug is a pharmaceutical product:
 (i) the form in which the drug is to be imported; and
 (ii) in the case of a drug referred to in paragraph (d) of the definition of drug in subregulation (20)—the strength of the active